ClinicalTrials.gg

Program

KN060

A development code. Also written as “KN060 Low”, “KN060 Middle” and “KN060 Hight”.

Its studies are mostly in Kidney Failure, Chronic · Essential Hypertension, led by Suzhou Alphamab.

Furthest: phase 2, since Dec 3, 20233 company-led studies, 3 open or runningNext primary completion: Dec 30, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Suzhou Alphamab33 open or runningphase 2since Dec 3, 2023Dec 3, 2023Dec 30, 2026phase 1 · NCT07191899

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 3, 2023First study: phase 2 study in Knee Arthroplasty, TotalFirst studyNCT06180889 · 241 enrolled · China
  2. Jun 6, 2025Phase 1 study in HypertensionNCT07191899 · 60 planned · China
  3. Sep 16, 2025Phase 2 study in End-Stage Renal Disease Requiring HaemodialysisNCT07201467 · 12 planned · China

Ahead

  1. Dec 30, 2026Primary completion: phase 1 study in HypertensionNCT07191899
  2. Aug 15, 2027Primary completion: phase 2 study in End-Stage Renal Disease Requiring HaemodialysisNCT07201467

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07201467End-Stage Renal Disease Requiring Haemodialysis · China2RecruitingAug 15, 202712
NCT07191899Hypertension · China1RecruitingDec 30, 202660
NCT06180889Knee Arthroplasty, Total · China2Active, not recruitingDec 15, 2025241

How it is read

Names in the registry

  • “KN060”, 2 entries
  • “KN060 Low”, 1 entry
  • “KN060 Middle”, 1 entry
  • “KN060 Hight”, 1 entry

Codes read as this program: KN060.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.